Natera Inc earnings missed by $0.15, revenue topped estimates
Natera Inc (NTRA) reported Q3 EPS of -$0.42, missing estimates by $0.15, but revenue of $794M exceeded expectations. The company forecasts FY 2026 revenue between $3.01B and $3.04B, higher than analyst consensus. NTRA's stock is up 12.93% in 3 months and 83.27% in 12 months.
How this was made
The 30-second read
Why it matters
Earnings miss may trigger a pullback, but raised guidance could attract long-term investors.
Market read
First report of Q3 results; material earnings data for traders.
What to watch
Strong cash position and pipeline progress could mitigate short-term EPS concerns.
Background
Natera is a genetic testing company focused on reproductive health and oncology, listed on NASDAQ.
Ticker impact
Natera reported Q3 EPS of -$0.42 missing estimates by $0.15 and revenue of $794M beating consensus, plus FY2026 revenue guidance raised to $3.01B-$3.04B.
likely downside as market prices in the EPS miss, though guidance lift may cushion the move.
Investors focus on EPS miss; revenue beat and higher guidance provide limited support, leading to net negative bias.
Market effects
May weigh on other prenatal testing and diagnostics firms as earnings expectations are reassessed.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
Guidance raise suggests upside potential if the market underestimates future revenue growth.
Key entities
- CompanyNatera Inc
Provider of genetic testing services, ticker NTRA.
